By Fineline Cube 
China-based Pediatrix Therapeutics announced that it has received marketing approval in Macau for its neffy (epinephrine nasal spray) for the emergency treatment of Type I allergic reactions (including anaphylaxis) in adults and children weighing ≥30kg.
Product Overview and Innovation
Neffy is an intranasal epinephrine product developed by ARS Pharmaceuticals, Inc. (Nasdaq: SPRY). The US firm granted Pediatrix the development and commercialization rights to the drug in Greater China through a licensing deal in January 2021. The product features an innovative intranasal delivery system, making it easy to use, compact, and portable, which enables rapid administration by patients or caregivers during emergencies.
Global Approval Status
Neffy 2 mg was approved in the US and European Union in August 2024, becoming the first non – injectable treatment product for Type I allergic reactions, including severe allergic reactions. Its 2 mg dosage form is currently awaiting regulatory decisions in China.-Fineline Info & Tech